Managing the Drug Discovery Process: How to Make It More Efficient and Cost-Effective thoroughly examines the current state of pharmaceutical research and development by providing chemistry-based perspectives on biomedical research, drug hunting and innovation. The book also considers the interplay of stakeholders, consumers, and the drug firm with attendant factors, including those that are technical, legal, economic, demographic, political, social, ecological, and infrastructural. Since drug research can be a high-risk, high-payoff industry, it is important to researchers to effectively and strategically manage the drug discovery process.
This book takes a closer look at increasing pre-approval costs for new drugs and examines not only why these increases occur, but also how they can be overcome to ensure a robust pharmacoeconomic future. Written in an engaging manner and including memorable insights, this book is aimed at redirecting the drug discovery process to make it more efficient and cost-effective in order to achieve the goal of saving countless more lives through science. A valuable and compelling resource, this is a must-read for all students and researchers in academia and the pharmaceutical industry.
1. Section A: Introduction and Overview - p. xx 2. 1: Backgrounder: Medicinal chemistry: Research, discovery, art, science - p. xx 3. Section B: Preprofessional Education - p. 29 4. 2: Introduction: Preprofessional education - p. 29 5. 3: Two-year certification and degree programs - p. 42 6. 4: Four-year undergraduate degree programs - p. 57 7. 5: The big decision - p. 88 8. Section C: Graduate and Professional Education - p. 99 9. 6: Graduate and postgraduate education at a crossroads - p. 99 10. 7: Master’s degree programs - p. 128 11. 8: Doctoral and professional programs - p. 139 12. 9: The big leap - p. 169 13. Section D: Research and Discovery - p. 179 14. 10: Drug discovery: Chaos can be your friend or your enemy - p. 179 15. Abstract - p. 179 16. 10.1 Introduction to selected aspects of biotechnology and pharmaceutical discovery R&D - p. 179 17. 10.2 Major issues including attrition, cost, financing, ROI, and timelines - p. 200 18. 10.3 Champions, teams, and project management - p. 231 19. 10.4 Recruiting, developing, compensating, and retaining valuable human resources - p. 238 20. 10.5 Multiple sites and outsourcing - p. 244 21. 10.6 Comparing and contrasting centers and sectors of innovation - p. 248 22. 10.7 BD including IP - p. 253 23. 10.8 Afterword - p. 259 24. 11: Drug discovery: Standing on the shoulders of giants - p. 279 25. Abstract - p. 279 26. 11.1 Introduction - p. 279 27. 11.2 Getting the basics right - p. 284 28. 11.3 Combinatorial chemistry - p. 293 29. 11.4 Peptoids - p. 298 30. 11.5 Mitochondria - p. 306 31. 11.6 Genomics + - p. 308 32. 11.7 Chemical biology + - p. 311 33. 11.8 Macromolecules - p. 315 34. 11.9 Computational technologies - p. 318 35. 11.10 Easy to forget - p. 332 36. 11.11 Alzheimer disease - p. 333 37. 11.12 Targets - p. 338 38. 11.13 Afterword - p. 376 39. 12: Research and discovery: The difficult we do immediately—The impossible takes only a little longer - p. 420 40. Section E: Chemical Development, Quality Requirements, and Regulatory Affairs - p. 436 41. 13: Turning a potent agent into a registered product - p. 436 42. 14: Chemical development: Synthetic studies and engineering aspects - p. 447 43. 15: Chemical development: Analytical studies - p. 458 44. 16: FDA path and process: Sponsor‘s regulatory tasks for drug approval - p. 466 45. Section F: Pharmaceutical Research and Development: Concluding Remarks - p. 485 46. 17: Epilogue - p. 485 47. Index - p. 493
Managing the Drug Discovery Process: How to Make It More Efficient and Cost-Effective thoroughly examines the current state of pharmaceutical research and development by providing chemistry-based perspectives on biomedical research, drug hunting and innovation. The book also considers the interplay of stakeholders, consumers, and the drug firm with attendant factors, including those that are technical, legal, economic, demographic, political, social, ecological, and infrastructural. Since drug research can be a high-risk, high-payoff industry, it is important to researchers to effectively and strategically manage the drug discovery process.
This book takes a closer look at increasing pre-approval costs for new drugs and examines not only why these increases occur, but also how they can be overcome to ensure a robust pharmacoeconomic future. Written in an engaging manner and including memorable insights, this book is aimed at redirecting the drug discovery process to make it more efficient and cost-effective in order to achieve the goal of saving countless more lives through science. A valuable and compelling resource, this is a must-read for all students and researchers in academia and the pharmaceutical industry.
1. Section A: Introduction and Overview - p. xx 2. 1: Backgrounder: Medicinal chemistry: Research, discovery, art, science - p. xx 3. Section B: Preprofessional Education - p. 29 4. 2: Introduction: Preprofessional education - p. 29 5. 3: Two-year certification and degree programs - p. 42 6. 4: Four-year undergraduate degree programs - p. 57 7. 5: The big decision - p. 88 8. Section C: Graduate and Professional Education - p. 99 9. 6: Graduate and postgraduate education at a crossroads - p. 99 10. 7: Master’s degree programs - p. 128 11. 8: Doctoral and professional programs - p. 139 12. 9: The big leap - p. 169 13. Section D: Research and Discovery - p. 179 14. 10: Drug discovery: Chaos can be your friend or your enemy - p. 179 15. Abstract - p. 179 16. 10.1 Introduction to selected aspects of biotechnology and pharmaceutical discovery R&D - p. 179 17. 10.2 Major issues including attrition, cost, financing, ROI, and timelines - p. 200 18. 10.3 Champions, teams, and project management - p. 231 19. 10.4 Recruiting, developing, compensating, and retaining valuable human resources - p. 238 20. 10.5 Multiple sites and outsourcing - p. 244 21. 10.6 Comparing and contrasting centers and sectors of innovation - p. 248 22. 10.7 BD including IP - p. 253 23. 10.8 Afterword - p. 259 24. 11: Drug discovery: Standing on the shoulders of giants - p. 279 25. Abstract - p. 279 26. 11.1 Introduction - p. 279 27. 11.2 Getting the basics right - p. 284 28. 11.3 Combinatorial chemistry - p. 293 29. 11.4 Peptoids - p. 298 30. 11.5 Mitochondria - p. 306 31. 11.6 Genomics + - p. 308 32. 11.7 Chemical biology + - p. 311 33. 11.8 Macromolecules - p. 315 34. 11.9 Computational technologies - p. 318 35. 11.10 Easy to forget - p. 332 36. 11.11 Alzheimer disease - p. 333 37. 11.12 Targets - p. 338 38. 11.13 Afterword - p. 376 39. 12: Research and discovery: The difficult we do immediately—The impossible takes only a little longer - p. 420 40. Section E: Chemical Development, Quality Requirements, and Regulatory Affairs - p. 436 41. 13: Turning a potent agent into a registered product - p. 436 42. 14: Chemical development: Synthetic studies and engineering aspects - p. 447 43. 15: Chemical development: Analytical studies - p. 458 44. 16: FDA path and process: Sponsor‘s regulatory tasks for drug approval - p. 466 45. Section F: Pharmaceutical Research and Development: Concluding Remarks - p. 485 46. 17: Epilogue - p. 485 47. Index - p. 493
